Overview

Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam

Status:
Recruiting
Trial end date:
2021-11-26
Target enrollment:
Participant gender:
Summary
The study is an open-label, fixed-sequence, cross-over study conducted at a single Clinical Unit to assess the pharmacokinetics (PK) of midazolam in healthy male and female (non-childbearing potential) subjects when administered alone and in combination with AZD4831 after multiple doses (once daily) of AZD4831 for 10 consecutive days.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Midazolam